Nothing Special   »   [go: up one dir, main page]

PL3349758T3 - Sposoby leczenia zakażeń wirusami arenaviridae - Google Patents

Sposoby leczenia zakażeń wirusami arenaviridae

Info

Publication number
PL3349758T3
PL3349758T3 PL16770866.8T PL16770866T PL3349758T3 PL 3349758 T3 PL3349758 T3 PL 3349758T3 PL 16770866 T PL16770866 T PL 16770866T PL 3349758 T3 PL3349758 T3 PL 3349758T3
Authority
PL
Poland
Prior art keywords
methods
virus infections
arenaviridae virus
treating arenaviridae
treating
Prior art date
Application number
PL16770866.8T
Other languages
English (en)
Inventor
Michael O' Neil Hanrahan Clarke
Joy Yang Feng
Robert Jordan
Richard L. Mackman
Adrian S. Ray
Dustin Siegel
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL3349758T3 publication Critical patent/PL3349758T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
PL16770866.8T 2015-09-16 2016-09-16 Sposoby leczenia zakażeń wirusami arenaviridae PL3349758T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219302P 2015-09-16 2015-09-16
US201562239696P 2015-10-09 2015-10-09
PCT/US2016/052092 WO2017049060A1 (en) 2015-09-16 2016-09-16 Methods for treating arenaviridae and coronaviridae virus infections

Publications (1)

Publication Number Publication Date
PL3349758T3 true PL3349758T3 (pl) 2022-09-12

Family

ID=56997582

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16770866.8T PL3349758T3 (pl) 2015-09-16 2016-09-16 Sposoby leczenia zakażeń wirusami arenaviridae
PL20201732T PL3785717T3 (pl) 2015-09-16 2016-09-16 Sposoby leczenia infekcji coronaviridae

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL20201732T PL3785717T3 (pl) 2015-09-16 2016-09-16 Sposoby leczenia infekcji coronaviridae

Country Status (24)

Country Link
US (5) US10251904B2 (pl)
EP (3) EP3349758B1 (pl)
JP (5) JP6742403B2 (pl)
KR (1) KR20180050742A (pl)
CN (5) CN115844896A (pl)
AU (3) AU2016323604B2 (pl)
BR (2) BR112018005048B8 (pl)
CA (1) CA2998189C (pl)
CY (1) CY1125089T1 (pl)
DK (2) DK3785717T3 (pl)
EA (1) EA038141B1 (pl)
ES (2) ES2918585T3 (pl)
HK (3) HK1255732A1 (pl)
HR (2) HRP20220355T1 (pl)
HU (2) HUE058737T2 (pl)
LT (2) LT3785717T (pl)
MA (2) MA42819A (pl)
MX (2) MX2018003161A (pl)
PL (2) PL3349758T3 (pl)
PT (2) PT3785717T (pl)
SG (2) SG10202001878WA (pl)
SI (2) SI3785717T1 (pl)
TW (1) TW201733595A (pl)
WO (1) WO2017049060A1 (pl)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2480559T3 (da) 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
PL2595980T3 (pl) 2010-07-22 2015-03-31 Gilead Sciences Inc Sposoby i związki do leczenia infekcji wirusowych Paramyxoviridae
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
PL3349758T3 (pl) 2015-09-16 2022-09-12 Gilead Sciences, Inc. Sposoby leczenia zakażeń wirusami arenaviridae
US11617753B2 (en) 2016-11-10 2023-04-04 Oyagen, Inc. Methods of treating and inhibiting Ebola virus infection
ES2961460T3 (es) * 2017-03-14 2024-03-12 Gilead Sciences Inc Métodos para tratar las infecciones por coronavirus felinas
CA3059777C (en) * 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP3651734B1 (en) 2017-07-11 2024-11-13 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
SG11202002295QA (en) * 2017-09-18 2020-04-29 Janssen Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP4491232A2 (en) 2017-12-07 2025-01-15 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN110724174B (zh) * 2019-09-10 2021-02-05 广州六顺生物科技股份有限公司 吡咯并三嗪类化合物、组合物及其应用
CN111265532A (zh) * 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用
EP4096678A1 (en) * 2020-01-27 2022-12-07 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
US11738025B2 (en) * 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TW202245800A (zh) * 2020-02-18 2022-12-01 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
CN113292565B (zh) * 2020-02-24 2023-01-31 浙江森科建设有限公司 核苷类化合物及其制备方法和应用
WO2021168930A1 (zh) * 2020-02-25 2021-09-02 顾世海 一种瑞德西韦的片剂及其制备方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) * 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN111205294B (zh) * 2020-02-27 2021-10-01 江苏阿尔法药业股份有限公司 一种瑞德西韦中间体的制备方法
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
CN111233929B (zh) * 2020-02-28 2023-02-28 成都阿奇生物医药科技有限公司 一种核苷类似物的氘代物及其制备方法和用途
WO2021175250A1 (en) * 2020-03-03 2021-09-10 Aptorum Therapeutics Limited Compounds and methods for treating diseases and/or conditions caused by coronavirus
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2，1-f][1，2，4]三嗪-4-胺的一种新合成方法
CN111116656A (zh) * 2020-03-04 2020-05-08 江苏福瑞康泰药业有限公司 一种瑞德西韦的制备方法
CN111269248A (zh) * 2020-03-05 2020-06-12 江苏福瑞康泰药业有限公司 一种核苷氨基磷酸酯类药物母液回收的新方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
CN115298181B (zh) 2020-03-12 2024-08-16 吉利德科学公司 制备1’-氰基核苷的方法
CN111393478B (zh) * 2020-03-13 2023-05-26 深圳市宝安区新材料研究院 一种瑞德西韦的合成方法
WO2021186438A1 (en) * 2020-03-16 2021-09-23 Bar-Ilan University Molecules that target proteins of coronaviruses and uses thereof as anti-viral "cocktail"
PH12022552324A1 (en) * 2020-03-23 2023-12-04 John M H Gregg Anti-viral compounds and methods for administration thereof
CN113493480A (zh) * 2020-04-03 2021-10-12 南京正大天晴制药有限公司 一种瑞德西韦异构体的制备及其分析方法
AU2021251689B2 (en) 2020-04-06 2024-06-13 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN116036031A (zh) * 2020-04-07 2023-05-02 齐鲁制药有限公司 一种含有瑞德西韦的药物组合物
CN113811309B (zh) * 2020-04-13 2023-05-05 山东华铂凯盛生物科技有限公司 用于治疗病毒感染的聚合物制剂及制备方法和用途
WO2021211757A1 (en) * 2020-04-14 2021-10-21 Oyagen, Inc. Method for treating arenaviridae infections
CN111848679A (zh) * 2020-04-17 2020-10-30 山东科巢生物制药有限公司 一种利用微通道反应技术合成瑞德西韦的方法
CN113521020B (zh) * 2020-04-18 2023-05-02 齐鲁制药有限公司 一种含有水溶性酸的瑞德西韦固体剂型
CN112778310A (zh) * 2020-04-20 2021-05-11 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN111393243B (zh) * 2020-04-22 2022-12-13 深圳市宝安区新材料研究院 一种磷手性核苷类药物的合成方法及该方法得到的药物
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
CN111494349A (zh) * 2020-04-30 2020-08-07 中国人民解放军空军军医大学 一种瑞德西韦口腔速溶膜及制备方法
CN113633617A (zh) * 2020-05-11 2021-11-12 齐鲁制药有限公司 一种含有瑞德西韦的固体分散体、固体剂型及制备方法
AU2021276914A1 (en) * 2020-05-20 2022-12-01 Lyrus Life Sciences Pvt Ltd Novel composition for the treatment of viral infections
US20230277524A1 (en) 2020-05-22 2023-09-07 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
IN202011022634A (pl) 2020-05-29 2020-10-09 Jubilant Generics Limited
EP3915548A1 (en) 2020-05-29 2021-12-01 Jubilant Generics Limited Transmucosal pharmaceutical compositions of antiviral drugs
WO2021243157A1 (en) 2020-05-29 2021-12-02 Gilead Sciences, Inc. Remdesivir treatment methods
US11020349B1 (en) * 2020-07-14 2021-06-01 Jubilant Generics Limited Transmucosal dosage forms of remdesivir
CN111620909B (zh) * 2020-06-05 2022-12-02 广东中科药物研究有限公司 一种瑞德西韦的前体药物及其制备方法与应用
CA3182179A1 (en) * 2020-06-11 2021-12-16 Fabio E.S. Souza Novel crystalline form of remdesivir
US20210393663A1 (en) * 2020-06-23 2021-12-23 Cai Gu Huang Pharmaceutical formulation containing active metabolites of remdesivir or its analog for inhalation
PH12022553530A1 (en) * 2020-06-24 2024-06-24 Gilead Sciences Inc 1'-cyano nucleoside analogs and uses thereof
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
CN111875638A (zh) * 2020-07-16 2020-11-03 江苏省原子医学研究所 一种瑞德西韦衍生物的制备方法、瑞德西韦衍生物及其应用
CN111961079A (zh) * 2020-07-17 2020-11-20 南京正济医药研究有限公司 一种瑞德西韦有关物质及其制备方法和应用
AU2021317323A1 (en) * 2020-07-27 2023-02-16 Microbio Pty Ltd A detection method for viral replication
CR20230100A (es) 2020-08-24 2023-04-28 Gilead Sciences Inc Compuestos fosfolípidos y usos de los mismos
WO2022047065A2 (en) 2020-08-27 2022-03-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN112358504A (zh) * 2020-09-28 2021-02-12 南京正济医药研究有限公司 一种瑞德西韦有关物质及其制备方法和用途
CN112194681A (zh) * 2020-09-29 2021-01-08 佛山科学技术学院 核苷酸长链氨基磷酸酯化合物、其药物组合物及其制备方法和应用
CN112194680A (zh) * 2020-09-29 2021-01-08 佛山科学技术学院 核苷酸氨基磷酸酯化合物、其药物组合物及其制备方法和应用
US11612614B2 (en) * 2020-10-20 2023-03-28 Anzalp Pharmasolutions Pvt. Ltd. Isomorphs of Remdesivir and methods for synthesis of same
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
US20240317754A1 (en) * 2020-12-30 2024-09-26 Southern University Of Science And Technology Methods and modified nucleosides for treating coronavirus infections
CN113754665B (zh) * 2020-12-30 2022-08-19 南方科技大学 一种核苷类化合物的制备方法
US20220241300A1 (en) * 2021-01-20 2022-08-04 Regents Of The University Of Minnesota Next generation remdesivir antivirals
US11998562B2 (en) 2021-01-25 2024-06-04 University Of South Florida Ophthalmological formulations for the prevention of a coronavirus infection
WO2022166581A1 (zh) * 2021-02-07 2022-08-11 石家庄迪斯凯威医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
CN113105504B (zh) * 2021-03-30 2024-06-04 澳门科技大学 Remdesivir衍生物、其类似物及其制备方法与应用
KR20230170745A (ko) 2021-04-16 2023-12-19 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
WO2023023527A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2023056936A1 (zh) * 2021-10-07 2023-04-13 南京知和医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
CN114213366A (zh) * 2022-01-17 2022-03-22 江西师范大学 一种氟代糖内酯合成方法
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
WO2023194840A1 (en) 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in covid-19
US20240051962A1 (en) * 2022-06-29 2024-02-15 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US11655255B2 (en) 2022-10-17 2023-05-23 Sph No.1 Biochemical & Pharmaceutical Co., Ltd. Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein
WO2024108130A1 (en) 2022-11-18 2024-05-23 Gilead Sciences, Inc. Methods for treating poxvirus infections
WO2024120464A1 (zh) * 2022-12-09 2024-06-13 深圳市塔吉瑞生物医药有限公司 核苷酸类似物及其组合物及用途
CN116410228A (zh) * 2023-05-04 2023-07-11 南京颐媛生物医学研究院有限公司 一种抗冠状病毒核苷类化合物的制备方法及其应用
CN117126199B (zh) * 2023-05-17 2024-12-06 江西师范大学 一种氟代瑞德西韦合成方法

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DE69115694T2 (de) 1990-06-13 1996-10-17 Arnold Newton Mass. Glazier Phosphorylierte prodrugs
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
JPH1017629A (ja) 1996-07-04 1998-01-20 Kayaku Akzo Kk ハードコート用樹脂組成物及びその硬化方法
US6887707B2 (en) 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
ATE254632T1 (de) 1998-03-03 2003-12-15 Novo Nordisk As Neue salzformn von (2e)-5-amino-5-methylhex-2- enolsäure n-methyl-n-((1r)-1-(methylcarbamoyl)-2- phruylrthyl) carbamoyl)-2-(2-naphtyl)ethyl)amid
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CA2326535A1 (en) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
DE69936998T2 (de) 1998-10-16 2008-05-21 Merck Sharp & Dohme Ltd., Hoddesdon Pyrazolotriazinderivate als gaba-rezeptorliganden
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
EP1181301A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Oligonucleotide synthesis with lewis acids as activators
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
WO2001019375A1 (en) 1999-09-15 2001-03-22 Biocryst Pharmaceuticals, Inc. Inhibiting t-cell proliferation
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
HUP0301112A3 (en) 2000-02-18 2005-04-28 Shire Biochem Inc Laval Method for the treatment or prevention of flavivirus infections using nucleoside analogues
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AP2006003708A0 (en) 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
CA2893174A1 (en) 2000-07-21 2002-01-31 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
PT2251015E (pt) 2000-10-18 2013-04-15 Gilead Pharmasset Llc Nucleosídeos modificados para o tratamento de infeções virais e de proliferação celular anormal
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
CA2434386C (en) 2001-01-22 2006-12-05 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
DE10145223A1 (de) 2001-09-13 2003-04-03 Basf Ag Verfahren zur Herstellung von meso-Zeaxanthin
JP2005536440A (ja) 2001-09-28 2005-12-02 イデニクス（ケイマン）リミテツド ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
AT410792B (de) 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung
EP1485396A2 (en) 2002-02-28 2004-12-15 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
RU2004128943A (ru) 2002-02-28 2005-04-20 Байота, Инк. (Us) Средства, имитирующие нуклеотиды, и их пролекарственные формы
US20040138170A1 (en) 2002-03-06 2004-07-15 Montgomery John A. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
AU2003232071A1 (en) 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
AU2003233667A1 (en) 2002-05-23 2003-12-12 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
JP2006519753A (ja) 2002-11-15 2006-08-31 イデニクス（ケイマン）リミテツド ２’−分枝ヌクレオシドおよびフラビウイルス科ウイルス突然変異
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
EP1646371A4 (en) 2003-06-26 2010-09-22 Biotron Ltd ANTIVIRAL COMPOSITIONS AND METHODS
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
JP2007501185A (ja) 2003-07-25 2007-01-25 イデニクス（ケイマン）リミテツド Ｃ型肝炎を含むフラビウイルス関連疾患を治療するためのプリンヌクレオシド類似体
CN1863813B (zh) 2003-08-27 2011-03-30 生物区科学管理控股有限公司 作为治疗剂的三环核苷或核苷酸
EP2295422A3 (de) 2004-03-16 2012-01-04 Boehringer Ingelheim International GmbH Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2568379A1 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
SI3109244T1 (sl) 2004-09-14 2019-06-28 Gilead Pharmasset Llc Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
CN101043893A (zh) 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
CA2584367A1 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
EP1814561A4 (en) 2004-10-29 2012-12-19 Biocryst Pharm Inc THEROPUTICAL FUROPYRIMIDINES AND THIENOPYRIMIDINES
DE602005009745D1 (de) 2004-12-16 2008-10-23 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
CA2600886A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
US7514410B2 (en) 2005-03-29 2009-04-07 Biocryst Pharmaceuticals, Inc. Hepatitis C therapies
US7405204B2 (en) 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
CA2612403C (en) 2005-06-24 2014-03-25 Biotron Limited Antiviral compounds and methods
WO2007038860A2 (en) 2005-10-03 2007-04-12 University Health Network Odcase inhibitors as anti-virals and antibiotics
ES2401099T3 (es) 2005-11-02 2013-04-16 Bayer Intellectual Property Gmbh Pirrolo[2,1-F] [1,2,4]-triazin-4-ilaminas como inhibidores de la quinasa IGF-1R para el tratamiento del cáncer y de otras enfermedades hiperproliferativas
KR101191682B1 (ko) 2005-12-01 2012-10-16 바실리어 파마슈티카 아게 에폭시부탄올 중간체의 제조 방법
AU2006320440B2 (en) 2005-12-02 2012-04-05 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
AU2006324098C1 (en) 2005-12-09 2011-12-08 F. Hoffmann-La Roche Ag Antiviral nucleosides
EP1971331A2 (en) 2005-12-09 2008-09-24 Basilea Pharmaceutica AG 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders
CA2637879A1 (en) 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2007097991A2 (en) 2006-02-16 2007-08-30 Pharmasset, Inc. Methods and kits for dosing of antiviral agents
DE102006015378A1 (de) 2006-04-03 2007-10-04 Ludwig-Maximilians-Universität München Verfahren zur Synthese von Organoelementverbindungen
AR061024A1 (es) 2006-05-22 2008-07-30 Novartis Ag Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
WO2008033466A2 (en) 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
JP2010508371A (ja) 2006-11-06 2010-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
AU2007338899A1 (en) 2006-12-20 2008-07-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US8071568B2 (en) 2007-01-05 2011-12-06 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
CN101611046A (zh) 2007-01-12 2009-12-23 拜奥克里斯特制药公司 抗病毒的核苷类似物
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2685520A1 (en) 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
NZ583652A (en) 2007-08-03 2012-06-29 Biotron Ltd Hepatitis c antiviral compositions and methods
KR101502533B1 (ko) 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
CA2722084C (en) 2008-04-23 2016-08-23 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
MX2011008409A (es) 2009-02-10 2011-10-21 Gilead Sciences Inc Análogos de carba-nucléosido para tratamiento antiviral.
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CA2755642A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
AU2010230008B2 (en) 2009-03-24 2015-06-04 Biocryst Pharmaceuticals, Inc. Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1- ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
DK2475657T3 (da) 2009-07-21 2013-09-23 Gilead Sciences Inc 5-Alkynylthien-2-ylcarboxylsyrer som inhibitorer af flaviviridae-vira
DK2480559T3 (da) 2009-09-21 2013-08-05 Gilead Sciences Inc Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger
DK2480552T3 (en) 2009-09-21 2017-02-20 Gilead Sciences Inc 2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
SG181757A1 (en) 2009-12-28 2012-07-30 Dev Center Biotechnology Novel pyrimidine compounds as mtor and pi3k inhibitors
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
DK2609923T3 (en) 2010-03-31 2017-09-18 Gilead Pharmasset Llc PROCEDURE FOR CRYSTALLIZING (S) -ISOPROPYL 2- (((S) (PERFLUORPHENOXY) (PHENOXY) PHOSPHORYL) AMINO) PROPANOATE
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
CN103052646A (zh) 2010-07-19 2013-04-17 吉里德科学公司 用于制备非对映异构体纯氨基磷酸酯前药的方法
PL2595980T3 (pl) 2010-07-22 2015-03-31 Gilead Sciences Inc Sposoby i związki do leczenia infekcji wirusowych Paramyxoviridae
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
AU2011306066B2 (en) 2010-09-20 2015-01-29 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
PE20140608A1 (es) * 2010-09-22 2014-06-12 Alios Biopharma Inc Analogos de nucleotidos sustituidos
ES2536831T3 (es) 2010-10-15 2015-05-29 Biocryst Pharmaceuticals, Inc. Métodos y composiciones para inhibición de polimerasa
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
WO2012087596A1 (en) 2010-12-20 2012-06-28 Gilead Sciences, Inc. Combinations for treating hcv
WO2012142085A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US8877733B2 (en) 2011-04-13 2014-11-04 Gilead Sciences, Inc. 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
UA114086C2 (xx) 2011-05-13 2017-04-25 Імуногенна композиція глікопротеїну g вірусу hendra і/або nipah
NZ623396A (en) 2011-09-16 2016-07-29 Gilead Pharmasset Llc Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013084165A1 (en) 2011-12-05 2013-06-13 Medivir Ab Hcv polymerase inhibitors
US20130143835A1 (en) 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
ES2671478T3 (es) 2012-08-31 2018-06-06 Novartis Ag Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
AU2013311705A1 (en) 2012-09-10 2015-02-05 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
WO2014042433A2 (en) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
JP2016504284A (ja) * 2012-11-16 2016-02-12 バイオクリスト ファーマスーティカルズ，インコーポレイテッドＢｉｏｃｒｙｓｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 抗ウイルス性アザ糖を含有するヌクレオシド
KR20150086325A (ko) 2012-11-19 2015-07-27 머크 샤프 앤드 돔 코포레이션 바이러스성 질환을 치료하기 위한 2''-알키닐 치환된 뉴클레오시드 유도체
CN105073766A (zh) 2012-12-21 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
WO2014116755A1 (en) * 2013-01-22 2014-07-31 Massachusetts Institute Of Technology Uses of dihydro bases
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
KR20160003700A (ko) 2013-04-12 2016-01-11 아칠리온 파르마세우티칼스 인코포레이티드 C형간염 바이러스의 치료를 위한 고활성 뉴클레오시드 유도체
US9542154B2 (en) 2013-06-25 2017-01-10 Intel Corporation Fused multiply add operations using bit masks
UA117375C2 (uk) 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
CA2923090C (en) 2013-09-11 2018-08-21 Poxel Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
AU2015212903A1 (en) 2014-01-30 2016-05-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection
EA030115B9 (ru) 2014-03-07 2018-09-28 Ф. Хоффманн-Ля Рош Аг Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
CA2948080A1 (en) 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
US9504701B2 (en) 2014-06-02 2016-11-29 The Board Of Regents Of The University Of Texas System Methods for treating viral infections using hydrogen sulfide donors
US9616076B2 (en) 2014-06-02 2017-04-11 The Board Of Regents Of The University Of Texas Systems Methods for treating viral infections using hydrogen sulfide donors
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
JP6506836B2 (ja) 2014-08-14 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
TWI740546B (zh) * 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
EP3240537B1 (en) 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
CN107109497A (zh) 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
WO2016120186A1 (en) 2015-01-27 2016-08-04 F. Hoffmann-La Roche Ag Recombinant hbv cccdna, the method to generate thereof and the use thereof
WO2016128335A1 (en) 2015-02-11 2016-08-18 F. Hoffmann-La Roche Ag Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
PL3349758T3 (pl) * 2015-09-16 2022-09-12 Gilead Sciences, Inc. Sposoby leczenia zakażeń wirusami arenaviridae
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
WO2018121678A1 (zh) 2016-12-29 2018-07-05 广东东阳光药业有限公司 一种抗病毒核苷类似物前药及其组合物、用途
SG11201907034PA (en) 2017-02-08 2019-08-27 Biotron Ltd Methods of treating influenza
ES2961460T3 (es) 2017-03-14 2024-03-12 Gilead Sciences Inc Métodos para tratar las infecciones por coronavirus felinas
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP3651734B1 (en) 2017-07-11 2024-11-13 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
CN111265532A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用
EP4096678A1 (en) 2020-01-27 2022-12-07 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
CN115298181B (zh) 2020-03-12 2024-08-16 吉利德科学公司 制备1’-氰基核苷的方法
AU2021251689B2 (en) 2020-04-06 2024-06-13 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
WO2021243157A1 (en) * 2020-05-29 2021-12-02 Gilead Sciences, Inc. Remdesivir treatment methods
WO2022047065A2 (en) 2020-08-27 2022-03-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Also Published As

Publication number Publication date
EP3349758A1 (en) 2018-07-25
DK3785717T3 (da) 2022-03-21
CN115844896A (zh) 2023-03-28
HRP20220740T1 (hr) 2022-11-11
CN115887465A (zh) 2023-04-04
EA201890494A1 (ru) 2018-10-31
CA2998189A1 (en) 2017-03-23
MX2018003161A (es) 2018-05-17
JP2018531227A (ja) 2018-10-25
BR112018005048B8 (pt) 2021-03-23
CN116617233A (zh) 2023-08-22
TW201733595A (zh) 2017-10-01
US10695361B2 (en) 2020-06-30
HUE057928T2 (hu) 2022-06-28
ES2909419T3 (es) 2022-05-06
AU2020233714B2 (en) 2022-11-24
DK3349758T3 (da) 2022-06-13
US20230027727A1 (en) 2023-01-26
US11007208B2 (en) 2021-05-18
AU2016323604A1 (en) 2018-03-29
HRP20220355T1 (hr) 2022-05-13
US10251904B2 (en) 2019-04-09
JP2023085459A (ja) 2023-06-20
US20190255085A1 (en) 2019-08-22
EP3785717B1 (en) 2022-01-05
PT3349758T (pt) 2022-07-13
BR122020020217B1 (pt) 2021-08-17
EP3785717A1 (en) 2021-03-03
SI3349758T1 (sl) 2022-08-31
AU2016323604B2 (en) 2020-07-09
JP2021107431A (ja) 2021-07-29
EP4088718A1 (en) 2022-11-16
BR112018005048B1 (pt) 2021-02-23
HUE058737T2 (hu) 2022-09-28
ES2918585T3 (es) 2022-07-19
US11382926B2 (en) 2022-07-12
LT3785717T (lt) 2022-04-11
HK1256872A1 (zh) 2019-10-04
EA038141B1 (ru) 2021-07-13
US20170071964A1 (en) 2017-03-16
SG10202001878WA (en) 2020-04-29
US20200352967A1 (en) 2020-11-12
AU2023200990A1 (en) 2023-03-23
JP7254738B2 (ja) 2023-04-10
CA2998189C (en) 2021-08-03
MA42819A (fr) 2018-07-25
CN108348526A (zh) 2018-07-31
US20210393659A1 (en) 2021-12-23
KR20180050742A (ko) 2018-05-15
PT3785717T (pt) 2022-04-14
JP2024081784A (ja) 2024-06-18
SG10202109869XA (en) 2021-10-28
CN114366745A (zh) 2022-04-19
EP3349758B1 (en) 2022-04-06
AU2020233714A1 (en) 2020-10-08
CY1125089T1 (el) 2023-06-09
JP2020111587A (ja) 2020-07-27
HK1255732A1 (zh) 2019-08-23
SI3785717T1 (sl) 2022-04-29
MA52371A (fr) 2021-09-22
JP6742403B2 (ja) 2020-08-19
LT3349758T (lt) 2022-07-11
WO2017049060A1 (en) 2017-03-23
HK1257628A1 (zh) 2019-10-25
MX2021005087A (es) 2022-08-18
PL3785717T3 (pl) 2022-05-02

Similar Documents

Publication Publication Date Title
HUE058737T2 (hu) Eljárások arenaviridae vírusok okozta fertõzések kezelésére
HK1258795A1 (zh) 絲狀病毒科病毒感染的治療方法
HK1244217A1 (zh) 用於治療蛋白質病的方法
IL256972A (en) Methods for detecting and treating low-virulence infections
HK1255481A1 (zh) 用於治療hcv的方法
SG11201706885RA (en) Novel treatment method
SG11201609908VA (en) Virus reduction method
IL249616A0 (en) Methods for treating inflammation
EP3313398A4 (en) METHODS OF TREATING HCV
PL3131890T3 (pl) Związki do leczenia zakażeń wirusowych
AP2016009014A0 (en) Method for treating hiv infection